Page 1

( Mark One ) 冈 Annual Report Pursuant to Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 For the fiscal year ended December 31 , 2020 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON , D.C. 20549 FORM 10 - K Transition Report Pursuant to Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 For the transition period from to Commission file number : 001-36440 Delaware ( State or other jurisdiction of incorporation ) Common Stock- $ 0.01 Par Value ( Title of each class ) AVANOS Avanos Medical , Inc. ( Exact name of registrant as specified in its charter ) Large accelerated filer Non - accelerated filer 5405 Windward Parkway Suite 100 South Alpharetta , Georgia ( Address of principal executive offices ) 30004 ( Zip code ) Registrant's telephone number , including area code : ( 844 ) 428-2667 Securities registered pursuant to Section 12 ( b ) of the Act : AVNS ( I.R.S. Employer Identification No. ) X ☐ ☐ 46-4987888 ( Trading Symbol ) Securities registered pursuant to Section 12 ( g ) of the Act : None New York Stock Exchange ( Name of each exchange on which registered ) No Indicate by check mark if the registrant is a well - known seasoned issuer , as defined in Rule 405 of the Securities Act . Yes Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15 ( d ) of the Act . Yes No X Indicate by check mark whether the registrant ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the registrant was required to file such reports ) , and ( 2 ) has been subject to such filing requirements for the past 90 days . Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S - T ( §232.405 of this chapter ) during the preceding 12 months ( or for such shorter period that the registrant was required to submit such files ) . Yes No Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S - K ( §229.405 of this chapter ) is not contained herein , and will not be contained , to the best of registrant's knowledge , in definitive proxy or information statements incorporated by reference in Part III of this Form 10 - K or any amendment to this Form 10 - K . Indicate by check mark whether the registrant is a large accelerated filer , an accelerated filer , a non - accelerated filer , or a smaller reporting company . See the definitions of " large accelerated filer , " " accelerated filer " and " smaller reporting company " in Rule 12b - 2 of the Exchange Act . Accelerated filer Emerging growth company Smaller reporting company If an emerging growth company , indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 ( a ) of the Exchange Act . Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404 ( b ) of the Sarbanes - Oxley Act ( 15 U.S.C. 7262 ( b ) ) by the registered public accounting firm that prepared or issued its audit report . Î Indicate by check mark whether the registrant is a shell company ( as defined in Rule 12b - 2 of the Act ) . Yes No X The aggregate market value of common stock held by non - affiliates or registrant on June 30 , 2020 was $ 1,403,310,663 . As of February 10 , 2021 , there were 47,965,374 shares of Avanos Medical , Inc. common stock outstanding . DOCUMENTS INCORPORATED BY REFERENCE 00 Certain information contained in the definitive Proxy Statement for the Avanos Annual Meeting of Stockholders to be held on April 29 , 2021 is incorporated by reference into Part III .